Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.
FDG‐PET/CT
early diagnosis
imaging
multiple myeloma
whole body MRI
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
received:
11
06
2024
accepted:
08
08
2024
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
aheadofprint
Résumé
This Good Practice Paper provides recommendations for the use of advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma. It describes how advanced imaging contributes to optimal healthcare resource utilisation by in newly diagnosed and relapsed myeloma, and provides a perspective on future directions of myeloma imaging, including machine learning assisted reporting.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–427.
Bernstein ZS, Kim EB, Raje N. Bone disease in multiple myeloma: biologic and clinical implications. Cells. 2022;11:2308. https://doi.org/10.3390/cells11152308
Terpos E, Ntanasis‐Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8:7.
Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma‐related complications. Haematologica. 2015;100:1254–1266.
Thorsteinsdottir S, Gislason G, Aspelund T, Sverrisdottir I, Landgren O, Turesson I, et al. Fractures and survival in multiple myeloma: results from a population‐based study. Haematologica. 2020;105:1067–1073.
Herget GW, Wäsch R, Klein L, Schmal H, Terpos E, Engelhardt M. Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state‐of‐the‐art treatment. Haematologica. 2020;105:859–861.
Bladé J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld‐Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.
Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657–664.
Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F‐FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206–e217.
Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M‐V, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302–e312.
Latifoltojar A, Boyd K, Riddell A, Kaiser M, Messiou C. Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: towards macro‐phenotype driven patient management. Magn Reson Imaging. 2021;75:60–64.
Bäuerle T, Hillengass J, Fechtner K, Zechmann CM, Grenacher L, Moehler TM, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole‐body versus spinal MR imaging. Radiology. 2009;252:477–485.
Stern S, Chaudhuri S, Drayson M, Henshaw S, Karunanithi K, Willis F, et al. Investigation and management of the monoclonal gammopathy of undetermined significance: a British Society for Haematology Good Practice Paper. Br J Haematol. 2023;202:734–744.
Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E, et al. Prospective comparison of 18‐FDG PET/CT and whole‐body diffusion‐weighted MRI in the assessment of multiple myeloma. Ann Hematol. 2020;99:2869–2880.
Westerland O, Amlani A, Kelly‐Morland C, Fraczek M, Bailey K, Gleeson M, et al. Comparison of the diagnostic performance and impact on management of 18F‐FDG PET/CT and whole‐body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging. 2021;48:2558–2565.
Messiou C, Porta N, Sharma B, Levine D, Koh D‐M, Boyd K, et al. Prospective evaluation of whole‐body MRI versus FDG PET/CT for lesion detection in participants with myeloma. Radiol Imaging Cancer. 2021;3:e210048.
Westerland OA, Pratt G, Kazmi M, El‐Najjar I, Streetly M, Yong K, et al. National survey of imaging practice for suspected or confirmed plasma cell malignancies. Br J Radiol. 2018;91:20180462.
Westerland O, Drinkwater KJ, Parikh J, Streetly M, Pratt G, Goh V, et al. Imaging in myeloma: a Royal College of Radiologists national survey of current imaging practice. Clin Radiol. 2021;76:820–828.
BSH. Poster abstract book. Br J Haematol. 2023;2023(201):31–118.
Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of 18F‐FDG‐PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116–125.
Moreau P, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, et al. Evaluation of the prognostic value of positron emission tomography‐computed tomography (PET‐CT) at diagnosis and follow‐up in transplant‐eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: results of the Cassiopet companion study. Blood. 2019;134:692.
Torkian P, Mansoori B, Hillengass J, Azadbakht J, Rashedi S, Lee SS, et al. Diffusion‐weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta‐analysis. Skeletal Radiol. 2023;52:565–583.
Messiou C, Giles S, Collins DJ, West S, Davies FE, Morgan GJ, et al. Assessing response of myeloma bone disease with diffusion‐weighted MRI. Br J Radiol. 2012;85:e1198–e1203.
Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for acquisition, interpretation, and reporting of whole‐body MRI in myeloma: myeloma response assessment and diagnosis system (MY‐RADS). Radiology. 2019;291:5–13.
Zormpas‐Petridis K, Tunariu N, Curcean A, Messiou C, Curcean S, Collins DJ, et al. Accelerating whole‐body diffusion‐weighted MRI with deep learning‐based denoising image filters. Radiol Artif Intell. 2021;3:e200279.
Wennmann M, Bauer F, Klein A, Chmelik J, Grözinger M, Rotkopf LT, et al. In vivo repeatability and multiscanner reproducibility of MRI radiomics features in patients with monoclonal plasma cell disorders: a prospective bi‐institutional study. Investig Radiol. 2023;58:253–264.
Keaveney S, Dragan A, Rata M, Blackledge M, Scurr E, Winfield JM, et al. Image quality in whole‐body MRI using the MY‐RADS protocol in a prospective multi‐centre multiple myeloma study. Insights Imaging. 2023;14:170.